Article
New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
Applied immunohistochemistry & molecular morphology : AIMM - 1 Jan 2019
Lasota Jerzy, Kowalik Artur, Felisiak-Golabek Anna, Zięba Sebastian, Wang Zeng-Feng, Miettinen Markku
Abstract excerpt
A great majority of gastrointestinal stromal tumors (GISTs) are primarily driven by gain-of-function KIT receptor tyrosine kinase mutations that subsequently lead to activation of phosphatidiylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway, a downstream effector of KIT signaling. KIT tyrosine kinase inhibitor, imatinib mesylate, has been successfully used for the treatment of primary,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.